CARUMONAM
CARUMONAM
- CAS:
- 87638-04-8
- MF:
- C12H14N6O10S2
- MW:
- 466.4
Suppliers by country/region
Company Type
Properties
- alpha
- D26 -45° (c = 1 in DMSO)
- Density
- 2.13±0.1 g/cm3(Predicted)
- pka
- -0.43±0.60(Predicted)
Safety Information
Use
A synthetic monobactam with activity against common pathogenic organisms similar to that of aztreonam. It is resistant to hydrolysis by the common plasmid and chromosomal β-lactamases, but it can be hydrolyzed by ESBLs. It is administered intravenously, achieving a concentration of c. 78 mg/L after a 20-min infusion of 1 g. The plasma halflife is 1.7 h and the plasma protein binding 18–28%. Carumonam is almost entirely eliminated in the glomerular filtrate, probenecid having no effect on excretion; 96% of labeled compound is found in the urine, with 3% in the feces. Between 68% and 91% of the dose appears in the urine within 24 h. Side effects and clinical use are similar to those of aztreonam.
0 India supplier list of "CARUMONAM"